Aelin Therapeutics is a biopharmaceutical VIB start-up company that has secured a 27 M€ investment to pioneer peptide-based novel modalities to create a powerful first-in-class antibiotics and agents against high-value undruggable human targets. The technology, branded Pept-ins™, harnesses the power of protein aggregation to induce specific functional knockdown of a target protein. It is based on the ground-breaking work of structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau (KU Leuven). The Pept-in™ technology allows for the rational design of novel peptide-based therapeutics and differentiates itself from other therapeutic modalities through its unique mode of action, its designability and broad target space.
Aelin Therapeutics is now recruiting to build a motivated and innovative team to realise the therapeutic potential of Pept-ins.